Avanos Medical to be Acquired for $25.00/Share in Definitive Merger Agreement
AVNS has more than doubled off its 52-week low of $9.303.
Summary
Avanos Medical announced a definitive merger agreement to be acquired for $25.00 per share in cash, while also reporting Q1 2026 results with revenue growth but decreased net income and negative operating cash flow.
Key Events · M&A and Partnerships · AVNS
-
Definitive Merger Agreement Announced
Avanos Medical has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash. This transaction, initially disclosed in an 8-K on April 14, 2026, will take the company private and delist its common stock from the NYSE.
-
Q1 2026 Revenue Increased
Net sales for the three months ended March 31, 2026, rose 8.8% to $182.2 million, up from $167.5 million in the prior-year period, primarily driven by strong demand in Specialty Nutrition Systems.
-
Profitability Declined in Q1
Operating income decreased by 13.6% to $8.9 million, and net income fell by 22.7% to $5.1 million ($0.11 diluted EPS) compared to $6.6 million ($0.14 diluted EPS) in Q1 2025.
-
Shift to Negative Operating Cash Flow
The company used $12.3 million in cash from operating activities in Q1 2026, a significant shift from providing $25.7 million in the same period last year, leading to a $24.2 million decrease in cash and cash equivalents during the quarter.
Analysis · AVNS · Industrial Applications And Services
Avanos Medical has entered into a definitive merger agreement to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash. This transaction, previously announced in an 8-K on April 14, 2026, will result in the company becoming privately held and its stock delisted from the NYSE. The offer price represents a slight premium to the current trading price, providing a clear exit for shareholders. This 10-Q also provides the full Q1 2026 financial results, which show mixed performance with revenue growth but declining profitability and a shift to negative operating cash flow, providing context for the acquisition.
At the time of this filing, AVNS was trading at $24.70 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.30 to $24.75. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.